- 1801. 5,10 methylenetetrahydrofolate
- [A folate-based biomodulator with potential antineoplastic activity. 5,10-methylenetetrahydrofolate (MTHF) stabilizes the covalent binding of the fluorouracil metabolite 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (FdUMP) to its target enzyme, thymidylate synthase, which results in inhibition of thymidylate synthase, depletion of thymidine triphosphate (TTP), a necessary constituent of DNA, and tumor cell death. Unlike leucovorin, MTHF, as the active form of folate, does not require metabolic activation and may increase the chemotherapeutic effects of fluorouracil with lower toxicity. ( NCI )] (UMLS (CSP) C0048858) =Organic Chemical; Pharmacologic Substance; Vitamin =folacin;
| - 1851. 5-FU/L-CF
- (UMLS (NCI) C0280780) =Therapeutic or Preventive Procedure
|
- 1802. 5,10,15,20-Tetra-(m-hydroxyphenyl)chlorin
- [An anticancer drug that is also used in cancer prevention. It belongs to the family of drugs called photosensitizing agents. ( NCI )] (UMLS (NCI) C0379149) =Organic Chemical; Pharmacologic Substance
| - 1852. 5-FU/L-CF/LEV
- (UMLS (NCI) C0281741) =Therapeutic or Preventive Procedure
|
- 1803. 5,10-Methylenetetrahydrofolate Reductase (NADPH) Gene
- [This gene is involved in folate metabolism and methionine biosynthesis. ( NCI )] (UMLS (NCI) C0919427) MTHFR;
MTHFR Gene =Gene or Genome ;
| - 1853. 5-FU/L-CF/MTX
- (UMLS (NCI) C0281749) =Therapeutic or Preventive Procedure
|
- 1804. 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(1-hydroxyethyl)-1-methoxy-, (8S-cis)-, hydrochloride
- (UMLS (NCI) C0969848) Daunomycinol HCl;
Duborimycin Hydrochloride;
Duborimycine, Hydrochloride;
=Organic Chemical; Pharmacologic Substance ;
| - 1854. 5-FU/L-OHP
- (UMLS (NCI) C0796511) Fluorouracil/Oxaliplatin =Therapeutic or Preventive Procedure
|
- 1805. 5,12-Naphthacenedione, 7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2, 3, 6-trideoxy-3-(4-morpholinyl)-.alpha.-L-lyxo-hexopyranosyl] oxy]-, hydrochloride, (8S-cis)-
- [A semisynthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin. As an antineoplastic agent, morpholinodoxorubicin is more potent than doxorubicin. Similar to doxorubicin, morpholinodoxorubicin intercalates into DNA and causes single- and double-strand breaks in DNA via inhibition of topoisomerase I and II. Unlike doxorubicin, this agent is metabolized in vivo to a DNA-alkylating derivative that forms DNA interstrand cross-links, thereby potentiating its doxorubicin-like cytotoxicity. (NCI04) ( NCI )] (UMLS (NCI) C0173377) =Organic Chemical; Pharmacologic Substance
| - 1855. 5-FU/L-PAM
- (UMLS (NCI) C0279387) =Therapeutic or Preventive Procedure
|
- 1806. 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-, hydrochloride
- [The hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. ( NCI )] (UMLS (NCI) C0282123) =Organic Chemical; Pharmacologic Substance ;
=(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione;
=DAUNORUBICIN HYDROCHLORIDE 20 MG | - 1856. 5-FU/L-PAM/TMX
- (UMLS (NCI) C0279232) =Therapeutic or Preventive Procedure ;
|
- 1807. 5,5'-[(2-Hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-4H-1-benzopyran-2-carboxylic Acid], Disodium Salt
- [The sodium salt form of cromolyn, a mast cell stabilizer with anti-inflammatory activity. Cromolyn sodium probably interferes with the antigen-stimulated calcium transport across the mast cell membrane, thereby inhibiting mast cell release of histamine, leukotrienes, and other substances that cause hypersensitivity reactions. Cromolyn sodium also inhibits eosinophil chemotaxis. ( NCI )] (UMLS (NCI) C0012694) =Organic Chemical; Pharmacologic Substance ;
=Chromones;
cromoglycic acid =CROMOLYN SODIUM 800 MCG/ACTUAT;
CROMOLYN SODIUM 100 MG;
CROMOLYN SODIUM 4 %;
CROMOLYN SODIUM 100 MG/5ML;
CROMOLYN SODIUM 10 MG/ML;
| - 1857. 5-FU/LEV
- (UMLS (NCI) C0279296) =Therapeutic or Preventive Procedure ;
|
- 1808. 5,5-Diphenyl-2,4-imidazolidinedione
- [anticonvulsant used in a wide variety of seizures; also an anti-arrhythmic and a muscle relaxant. ( CSP )] (UMLS (NCI) C0031507) =Organic Chemical; Pharmacologic Substance =[CN400] ANTICONVULSANTS;
hydantoin =5,5-Diphenyl-2,4-imidazolidinedione, Monosodium Salt;
Fosphenytoin;
PHENYTOIN SODIUM EXTENDED;
5,5-Diphenyl-2,4-imidazolidinedione, Monosodium Salt;
PHENYTOIN SODIUM EXTENDED;
PHENYTOIN 125 MG/5ML;
PHENYTOIN 50 MG;
PHENYTOIN 30 MG/5ML;
PHENYTOIN 100 MG | - 1858. 5-FU/LEV/MOAB 17-1A
- (UMLS (NCI) C0338293) =Therapeutic or Preventive Procedure
|
- 1809. 5,5-Diphenyl-2,4-imidazolidinedione, Monosodium Salt
- [The sodium salt form of phenytoin, a hydantoin derivate and non-sedative antiepileptic agent with anticonvulsant activity. Phenytoin sodium promotes sodium efflux from neurons located in the motor cortex, thereby stabilizing the neuron and inhibiting synaptic transmission. This leads to a reduction in posttetanic potentiation at synapses, an inhibition of repetitive firing of action potentials and ultimately inhibits the spread of seizure activity. ( NCI )] (UMLS (NCI) C0237417) =Organic Chemical; Pharmacologic Substance =5,5-Diphenyl-2,4-imidazolidinedione;
=PHENYTOIN SODIUM 100 MG;
PHENYTOIN SODIUM 125 MG/5ML;
PHENYTOIN SODIUM 50 MG/ML;
PHENYTOIN SODIUM 30 MG;
PHENYTOIN SODIUM 300 MG;
PHENYTOIN SODIUM 200 MG;
| - 1859. 5-FU/MeCCNU
- (UMLS (NCI) C0280524) =Therapeutic or Preventive Procedure
|
- 1810. 5,6-Dimethylxanthenone-4-Acetic Acid
- [An anticancer drug that belongs to the family of drugs called angiogenesis inhibitors. ( NCI )] (UMLS (NCI) C0081181) =Organic Chemical; Pharmacologic Substance
| - 1860. 5-FU/MeCCNU/SZC/VCR
- (UMLS (NCI) C0066687) =Therapeutic or Preventive Procedure ;
|
- 1811. 5,7-Dichloro-8-hydroxyquinoline
- [A synthetic quinoline derivative with antibacterial activity. Although the mechanism of action is not fully understood, topical administration of chloroxine diminishes mitotic activity in the epidermis, thereby reducing excessive scaling associated with dandruff or seborrheic dermatitis of the scalp, including psoriasis and eczema. ( NCI )] (UMLS (NCI) C0055461) =Organic Chemical; Pharmacologic Substance =Chloroquinolinols;
[DE400] SOAPS/SHAMPOOS/SOAP-FREE CLEANSERS =CHLOROXINE 2 % | - 1861. 5-FU/MeCCNU/VCR
- (UMLS (NCI) C0066686) =Therapeutic or Preventive Procedure ;
|
- 1812. 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy Benzoic Acid
- [A compound isolated from strains of Streptomyces griseolavendus that may exert antitumor activity by inhibition of protein tyrosine kinase and tubulin polymerization. (NCI) ( NCI )] (UMLS (NCI) C0064695) =Organic Chemical; Pharmacologic Substance ;
| - 1862. 5-FU/MITO
- (UMLS (NCI) C0279374) =Therapeutic or Preventive Procedure
|
- 1813. 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-3H-1,2,4-Triazol-3-one
- [A small molecule, high-affinity substance P antagonist (SPA) with antiemetic activity. Crossing the blood brain barrier, aprepitant binds selectively to the human substance P/neurokinin receptor in the central nervous system (CNS), thereby inhibiting receptor binding of endogenous substance P and substance P-induced emesis. This agent has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors. ( NCI )] (UMLS (NCI) C1176306) APREPITANT;
APREPITANT UNIDENTIFIED;
APREPITANT PREPARATION;
APREPITANT UNIDENTIFIED =Organic Chemical; Pharmacologic Substance =[GA700] ANTIEMETICS;
Unclassified Ingredients =APREPITANT 125 MG;
APREPITANT 80 MG;
APREPITANT 125MG X1/80MG X2 CAP,PKT,3 | - 1863. 5-FU/MITO/MTX
- (UMLS (NCI) C0278904) =Therapeutic or Preventive Procedure
|
- 1814. 5-((3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl)-2-(2-(1H-tetrazol-5-yl)phenyl)pyridine
- [A nonpeptide angiotensin II receptor antagonist with antihypertensive activity. Forasartan selectively competes with angiotensin II for the binding of the angiotensin II (AT1) receptor subtype 1 in vascular smooth muscle, thereby blocking angiotensin II-mediated vasoconstriction resulting in vascular dilatation. In addition, the antagonistic effect on AT1 in the adrenal gland, prevents angiotensin II-induced stimulation of aldosterone synthesis and secretion by the adrenal cortex. This blocks the effects of aldosterone leading to an increase in sodium excretion and water and eventually a reduction in plasma volume and blood pressure. ( NCI )] (UMLS (NCI) C0250070) =Organic Chemical; Pharmacologic Substance ;
| - 1864. 5-FU/MITO/SZC
- (UMLS (NCI) C0082637) =Therapeutic or Preventive Procedure
|
- 1815. 5-(1,2-Dithiolan-3-yl)pentanoic Acid
- [A naturally occurring micronutrient, synthesized in small amounts by plants and animals (including humans), with potential chemopreventive and protective properties. Alpha-lipoic acid acts as a free radical scavenger and assists in repairing oxidative damage, regenerates endogenous antioxidants, including vitamin C, E and glutathione. This antioxidant also promotes glutathione synthesis. In addition, alpha-lipoic acid exerts metal chelating capacities and functions as a cofactor in various mitochondrial enzyme complexes involved in the decarboxylation of alpha-keto acids. ( NCI )] (UMLS (NCI) C0023791) =Organic Chemical; Pharmacologic Substance; Vitamin
| - 1865. 5-FU/MITO/VCR
- (UMLS (NCI) C0060627) =Therapeutic or Preventive Procedure ;
|
- 1816. 5-(2-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-Indol-2-one Monohydrochloride
- [The hydrochloride salt form of ziprasidone, a benzothiazolylpiperazine derivative and an atypical antipsychotic agent with an antischizophrenic property. Ziprasidone hydrochloride functions as an antagonist at the dopamine D2 and serotonin 5-HT2A and 5-HT1D receptors, and as an agonist at the 5-HT1A receptor. Ziprasidone hydrochloride also inhibits synaptic reuptake of serotonin and norepinephrine. The mechanism of action by which ziprasidone hydrochloride exerts its antischizophrenic effect is unknown but is potentially mediated through a combination of dopamine D2 and serotonin 5-HT2 antagonism. This agent also has antagonistic activity against histamine H1 and alpha-1-adrenergic receptors. ( NCI )] (UMLS (NCI) C0380392) =Organic Chemical; Pharmacologic Substance ;
| - 1866. 5-FU/MMPR/PALA
- (UMLS (NCI) C0278682) =Therapeutic or Preventive Procedure
|
- 1817. 5-(bis-(2-Chloroethyl) Amino) Uracil
- [Nitrogen mustard derivative of URACIL. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. ( MSH )] (UMLS (NCI) C0041920) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
=Nitrogen Mustard Compound;
2, 4-Dioxopyrimidine;
Antineoplastic Alkylating Agent;
| - 1867. 5-FU/MTX
- (UMLS (NCI) C0280603) =Therapeutic or Preventive Procedure
|
- 1818. 5-(o-Chlorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridinium Chloride
- [The hydrochloride salt form of ticlopidine, a thienopyridine derivative with anticoagulant property. Ticlopidine hydrochloride irreversibly inhibits adenosine-diphosphate (ADP)-induced platelet-fibrinogen binding by binding to the glycoprotein (GP) IIb/IIIA complex, one of the two purinergic receptors activated by ADP. Inhibition of the receptor activation causes the inhibition of adenylyl cyclase, results in decreased levels of cyclic adenosine monophosphate and thereby interferes with platelet membrane function and subsequent, platelet-platelet interaction, release of platelet granule constituents and prolongation of bleeding time. ( NCI )] (UMLS (NCI) C0000598) =Organic Chemical; Pharmacologic Substance
| - 1868. 5-FU/MTX/PALA
- (UMLS (NCI) C0280516) =Therapeutic or Preventive Procedure ;
|
- 1819. 5-ALA
- [A drug used in photodynamic therapy that is absorbed by tumor cells; when exposed to light, it becomes active and kills the cancer cells. ( NCI )] (UMLS (NCI) C0002563) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Biologically Active Substance
| - 1869. 5-FU/MTX/PRED/TSPA/VBL
- (UMLS (NCI) C0279275) =Therapeutic or Preventive Procedure ;
|
- 1820. 5-Amino-2-hydroxybenzoic Acid
- [An agent derived from sulfasalazine, an antiinflammatory agent. Mesalamine may reduce inflammation through inhibition of cyclooxygenase and prostaglandin production. Following rectal or oral administration, only a small amount of mesalamine is absorbed; the remainder, acting topically, reduces bowel inflammation, diarrhea, rectal bleeding and stomach pain. (NCI04) ( NCI )] (UMLS (NCI) C0127615) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
=Aminosalicylic Acids;
[GA900] GASTRIC MEDICATIONS, OTHER;
[RS100] ANTI-INFLAMMATORIES, RECTAL;
=MESALAMINE 250 MG;
MESALAMINE 500 MG;
MESALAMINE 400 MG;
MESALAMINE 4 GM/60ML | - 1870. 5-FU/MTX/TMX
- (UMLS (NCI) C0279041) =Therapeutic or Preventive Procedure
|
- 1821. 5-Amino-6-(70-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpicolinic Acid
- [An aminoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces flocculus. Streptonigrin complexes with DNA and topoisomerase II, resulting in DNA cleavage and inhibition of DNA replication and RNA synthesis. This agent also acts as a reverse transcriptase inhibitor and causes free radical-mediated cellular damage. (NCI04) ( NCI )] (UMLS (NCI) C0038427) =Organic Chemical; Antibiotic ;
| - 1871. 5-FU/MTX/TMX/TSPA
- (UMLS (NCI) C0280700) =Therapeutic or Preventive Procedure
|
- 1822. 5-AZA-dCyd/IDA
- (UMLS (NCI) C0279499) =Therapeutic or Preventive Procedure
| - 1872. 5-FU/MTX/TSPA
- (UMLS (NCI) C0244554) =Therapeutic or Preventive Procedure
|
- 1823. 5-Chloro-2,4-pyridinediol
- [A pyridine derivative with antitumor activity. Gimeracil enhances the antitumor activity of fluoropyrimidines by competitively and reversibly inhibiting the enzyme dihydropyrimidine dehydrogenase causing decreased degradation of the fluoropyrimidines. ( NCI )] (UMLS (NCI) C0535459) =Organic Chemical; Pharmacologic Substance
| - 1873. 5-FU/MTX/VBL
- (UMLS (NCI) C0279825) =Therapeutic or Preventive Procedure
|
- 1824. 5-Chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl) Pyridine
- [A synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic ,and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis. ( NCI )] (UMLS (NCI) C0972314) Etoricoxib;
ETORICOXIB UNIDENTIFIED;
=Organic Chemical; Pharmacologic Substance ;
| - 1874. 5-FU/MTX/VCR
- (UMLS (NCI) C0078399) =Therapeutic or Preventive Procedure
|
- 1825. 5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
- [barbituric acid derivative that acts as a nonselective central nervous system depressant. ( CSP )] (UMLS (NCI) C0031412) =Organic Chemical; Pharmacologic Substance ;
=[CN400] ANTICONVULSANTS;
barbiturate;
[CN300] SEDATIVES/HYPNOTICS;
[CN301] BARBITURIC ACID DERIVATIVE, SEDATIVES/HYPNOTICS =2-Deoxyphenobarbital;
PHENOBARBITAL SODIUM;
PHENOBARBITAL 100 MG;
PHENOBARBITAL 15 MG;
PHENOBARBITAL 15 MG/ML;
PHENOBARBITAL 16 MG;
PHENOBARBITAL 16.2 MG;
PHENOBARBITAL 15 MG/5ML;
PHENOBARBITAL 16.2 MG/5ML;
PHENOBARBITAL 18.5 MG/5ML;
PHENOBARBITAL 30 MG;
PHENOBARBITAL 20 MG/5ML;
PHENOBARBITAL 50 MG;
PHENOBARBITAL 65 MG;
PHENOBARBITAL 8 MG;
PHENOBARBITAL 90 MG;
PHENOBARBITAL 32 MG;
PHENOBARBITAL 45 MG;
PHENOBARBITAL 60 MG;
PHENOBARBITAL 97.2 MG;
PHENOBARBITAL 20 MG;
PHENOBARBITAL 7.5 MG;
PHENOBARBITAL 48.6 MG;
PHENOBARBITAL 40 MG;
PHENOBARBITAL 160 MG;
PHENOBARBITAL 200 MG;
Phenobarbital 0.4 MG/ML;
PHENOBARBITAL 21.6 MG/5ML;
PHENOBARBITAL 8.1 MG | - 1875. 5-FU/PALA
- (UMLS (NCI) C0280504) =Therapeutic or Preventive Procedure ;
|
- 1826. 5-Ethynyl-2,4(1H,3H)-pyrimidinedione
- [An anticancer drug that increases the effectiveness of fluorouracil. Also called eniluracil. ( NCI )] (UMLS (NCI) C0098361) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
| - 1876. 5-FU/PBA
- (UMLS (NCI) C0392930) =Therapeutic or Preventive Procedure ;
|
- 1827. 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione
- [An anticancer drug that belongs to the family of drugs called antimetabolites. ( NCI )] (UMLS (NCI) C0016778) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance
| - 1877. 5-FU/PRED/VCR
- (UMLS (NCI) C0279786) =Therapeutic or Preventive Procedure
|
- 1828. 5-Fluoro-2-Deoxycytidine
- [An antimetabolite consisting of a fluorinated pyrimidine analog with potential antineoplastic activity. As a prodrug, 5-fluoro-2-deoxycytidine is converted intracellularly, by deaminases, to the cytotoxic agent 5-Fluorouracil (5-FU). 5-FU is subsequently metabolized to active metabolites including 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP binds to and inhibits thymidylate synthase, thereby reducing the production of thymidine monophosphate leading to depletion of thymidine triphosphate. This inhibits DNA synthesis and cell division. FUTP competes with uridine triphosphate for incorporation into the RNA strand leading to an inhibition of RNA and protein synthesis. Other fluorouracil metabolites also get incorporated into both DNA and RNA, thereby further hampering cellular growth. ( NCI )] (UMLS (NCI) C0049174) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
| - 1878. 5-FU/SMS 201-995 pa
- (UMLS (NCI) C0338277) =Therapeutic or Preventive Procedure ;
|
- 1829. 5-Fluoropyrimidinone
- [A fluoronucleoside that inhibits pyrimidine synthesis, interfering with DNA synthesis. ( NCI )] (UMLS (NCI) C0393034) =Organic Chemical; Pharmacologic Substance ;
| - 1879. 5-FU/SZC
- (UMLS (NCI) C0278920) =Therapeutic or Preventive Procedure
|
- 1830. 5-Fluorouracil/epi
- [An injectable collagen matrix gel containing the antimetabolite fluorouracil and the symhathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with uracil during RNA synthesis whereas another active metabolite 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate inhibits thymidylate synthase, thereby interfering with DNA synthesis. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of fluorouracil into the tumor tissue and reduce dispersion to the surrounding tissues thereby enhancing the local concentration of fluorouracil and increasing its anti-tumor activity. Intratumoral injection of fluorouracil combined with epinephrine may potentially increase chemotherapeutic efficacy compared to systemic administration and reduce systemic toxicity and side effects. ( NCI )] (UMLS (NCI) C0281426) =Clinical Drug
| - 1880. 5-FU/TAU
- (UMLS (NCI) C0281354) =Therapeutic or Preventive Procedure
|
- 1831. 5-Formyl Tetrahydrofolate
- (UMLS (NCI) C0520456) =Organic Chemical; Vitamin ;
| - 1881. 5-FU/TAX
- (UMLS (NCI) C0678091) =Therapeutic or Preventive Procedure
|
- 1832. 5-Formyl-5,6,7,8-tetrahydrofolic Acid
- [USP lists as an antidote to folate antagonists and an agent for treatment of folate deficiency anemias. ( CSP )] (UMLS (NCI) C0023413) =Organic Chemical; Pharmacologic Substance; Vitamin =formyltetrahydrofolate;
folacin;
[VT102] FOLIC ACID/LEUCOVORIN;
=Calcium (6S)-Folinate;
| - 1882. 5-FU/TMTX
- (UMLS (NCI) C0678039) =Therapeutic or Preventive Procedure ;
|
- 1833. 5-FU/FUDR
- (UMLS (NCI) C0280815) =Therapeutic or Preventive Procedure ;
| - 1883. 5-FU/TXT
- (UMLS (NCI) C0677975) =Therapeutic or Preventive Procedure
|
- 1834. 5-FU/G-CSF/HU/IFN-A
- (UMLS (NCI) C0338187) =Therapeutic or Preventive Procedure ;
| - 1884. 5-FU/VNB
- (UMLS (NCI) C0281257) =Therapeutic or Preventive Procedure ;
|
- 1835. 5-FU/G-CSF/IFN-A
- (UMLS (NCI) C0338151) =Therapeutic or Preventive Procedure
| - 1885. 5-FU/VP-16
- (UMLS (NCI) C0281647) =Therapeutic or Preventive Procedure ;
|
- 1836. 5-FU/GAN
- (UMLS (NCI) C0281382) =Therapeutic or Preventive Procedure ;
| - 1886. 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)-
- [A synthetic prostamide and structural prostaglandin analogue with ocular hypotensive activity. Bimatoprost mimics the effects of the endogenous prostamides and reduces intracocular pressure by increasing outflow of aqueous humor through both the pressure-sensitive outflow pathway (the trabecular meshwork), and the pressure-insensitive outflow pathway (the uveoscleral routes). It is not clear whether bimatoprost lowers intraocular pressure by stimulating F-Prostanoid receptors or by acting on specific prostamide receptors. ( NCI )] (UMLS (NCI) C0937917) Bimatoprost;
BIMATOPROST PREPARATION;
BIMATOPROST UNIDENTIFIED;
=Lipid; Pharmacologic Substance ;
=[OP109] ANTIGLAUCOMA, OTHER;
Unclassified Ingredients =BIMATOPROST 0.03 %;
|
- 1837. 5-FU/HMM/MITO
- (UMLS (NCI) C0279184) =Therapeutic or Preventive Procedure
| - 1887. 5-Heptenoic Acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl Ester,(5Z)-
- [A synthetic lipophilic isopropyl ester prodrug of the active compound travoprost free acid, a prostaglandin F2alpha analog with anti-glaucoma property. Upon administration, travoprost is hydrolysed to a free acid by corneal esterases, and then selectively stimulating the prostaglandin F (FP prostanoid) receptor, thereby increasing the uveoscleral outflow which leads to a reduction in intra-ocular pressure. ( NCI )] (UMLS (NCI) C0937916) Travoprost;
TRAVOPROST PREPARATION;
TRAVOPROST UNIDENTIFIED;
=Organic Chemical; Pharmacologic Substance ;
=[OP109] ANTIGLAUCOMA, OTHER;
Unclassified Ingredients =TRAVOPROST 0.004 %;
|
- 1838. 5-FU/HU
- (UMLS (NCI) C0280678) =Therapeutic or Preventive Procedure
| - 1888. 5-HIAA
- [5HIAA. A breakdown product of serotonin that is excreted in the urine. Serotonin is a hormone found at high levels in many body tissues. Serotonin and 5HIAA are produced in excess amounts by carcinoid tumors, and levels of these substances may be measured in the urine to test for carcinoid tumors. ( NCI )] (UMLS (NCI) C0020361) =Organic Chemical; Biologically Active Substance ;
|
- 1839. 5-FU/HU/IFN-A
- (UMLS (NCI) C0338175) =Therapeutic or Preventive Procedure
| - 1889. 5-HT-3
- [Serotonin 5-HT-3 Receptor, encoded by the human HTR3 gene, is one of the several different receptors for serotonin (5-hydroxytryptamine, 5-HT), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. Whereas all other known serotonin receptor subtypes are G protein-coupled receptors, this receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel. Two isoforms, 1/5-HT3R-AS and 2/5-HT3R-AL, are produced by alternative splicing. (From OMIM, Swiss-Prot and NCI) ( NCI )] (UMLS (NCI) C0295352) =Amino Acid, Peptide, or Protein; Receptor ;
|
- 1840. 5-FU/HU/IUDR
- (UMLS (NCI) C0280826) =Therapeutic or Preventive Procedure
| - 1890. 5-Hydroxy-6-methyl-3,4-pyridinedimethanol Hydrochloride
- [The hydrochloride salt form of pyridoxine, a water-soluble vitamin B. Pyridoxine hydrochloride is converted into the active form, pyridoxal 5'-phosphate (PLP), an essential cofactor in many enzymatic activities including synthesis of amino acids, neurotransmitters, and sphingolipids. This vitamin is essential to red blood cell, nervous system, and immune systems functions and helps maintain normal blood glucose levels. ( NCI )] (UMLS (NCI) C0700496) =Organic Chemical; Pharmacologic Substance; Vitamin =[VT104] PYRIDOXINE;
=PYRIDOXINE HCL 0.3 MG;
MERITENE POWDER (CHOCOLATE);
MERITENE POWDER (MILK CHOCOLATE);
MERITENE POWDER More… |
- 1841. 5-FU/HU/TAX
- (UMLS (NCI) C0393082) =Therapeutic or Preventive Procedure
| - 1891. 5-Hydroxytryptamine (Serotonin) Receptor 2A Gene
- [This gene plays a role in G protein-coupled receptor signal transduction and sterol metabolism. ( NCI )] (UMLS (NCI) C1415809) HTR2A;
HTR2A Gene =Gene or Genome |
- 1842. 5-FU/ICI D1694
- (UMLS (NCI) C0677774) =Therapeutic or Preventive Procedure
| - 1892. 5-Hydroxytryptamine (Serotonin) Receptor 3A Gene
- [This gene plays a role in neurotransmitter modulation and in chaperone activity. ( NCI )] (UMLS (NCI) C1333933) HTR3A;
HTR3A Gene =Gene or Genome ;
|
- 1843. 5-FU/ICRF-159/MeCCNU
- (UMLS (NCI) C0279362) =Therapeutic or Preventive Procedure
| - 1893. 5-Iodo-2-pyrimidinone-2'-deoxyribose
- [An oral prodrug of 5-iododeoxyuridine (IUdR), an iodinated analogue of deoxyuridine and radiosensitizing agent. 5-Iodo-2-pyrimidinone-2-deoxyribose (IPdR) is efficiently converted to IUdR by a hepatic aldehyde oxidase. This results in increased IUdR plasma levels compared to oral IPdR and increased toxicity profile compared to intravenous administered IUdR. IUdR is incorporated into DNA during the S-phase of the cell cycle, thereby sensitizing cells to ionizing radiation by increasing DNA strand breaks. ( NCI )] (UMLS (NCI) C0088688) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance
|
- 1844. 5-FU/IFN-A
- (UMLS (NCI) C0338085) =Therapeutic or Preventive Procedure
| - 1894. 5-isoandrosterone
- [A 17-ketosteroid which excreted in the urine as a metabolite of steroid hormones. The most common form of etiocholanolone present in the urine is the sulfate salt. This agent, also known as 5-isoandrosterone, may be used to evaluate adrenal cortex function, bone marrow performance and, in neoplastic disease, for immunostimulation. (NCI04) ( NCI )] (UMLS (NCI) C0015124) =Steroid; Hormone ;
|
- 1845. 5-FU/IFN-A/IL-2
- (UMLS (NCI) C0338141) =Therapeutic or Preventive Procedure
| - 1895. 5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-,(1S)-, ethanedioate(1:1)
- [The oxalate salt of escitalopram, a pure S-enantiomer of the racemic bicyclic phthalane derivative citalopram, with antidepressant activity. As a selective serotonin reuptake inhibitor (SSRI), escitalopram blocks the reuptake of serotonin by neurons in the central nervous system (CNS), thereby potentiating CNS serotonergic activity. ( NCI )] (UMLS (NCI) C1170746) Escitalopram Oxalate;
ESCITALOPRAM OXALATE UNIDENTIFIED;
ESCITALOPRAM OXALATE PREPARATION;
ESCITALOPRAM OXALATE UNIDENTIFIED =Organic Chemical; Pharmacologic Substance =ESCITALOPRAM;
Unclassified Ingredients =Escitalopram 10 MG Oral Tablet;
Escitalopram 5 MG Oral Tablet;
Escitalopram 20 MG Oral Tablet;
Escitalopram 1 MG/ML Oral Solution |
- 1846. 5-FU/IFN-A/MITO
- (UMLS (NCI) C0338093) =Therapeutic or Preventive Procedure
| - 1896. 5-MeC
- [A crystalline, carcinogenic aromatic hydrocarbon consisting of four fused rings and produced by the incomplete combustion of organic matter. 5-Methylchrysene is primarily found in gasoline exhaust and tobacco smoke. 5-Methylchrysene is reasonably anticipated to be a human carcinogen. (NCI05) ( NCI )] (UMLS (NCI) C0049304) =Organic Chemical; Hazardous or Poisonous Substance
|
- 1847. 5-FU/IFN-A/PALA
- (UMLS (NCI) C0338107) =Therapeutic or Preventive Procedure ;
| - 1897. 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
- [substituted benzimidazole used as a gastric acid secretion inhibitor. ( CSP )] (UMLS (NCI) C0028978) =Organic Chemical; Pharmacologic Substance ;
=[GA300] ANTIULCER AGENTS;
benzimidazole;
gastric juice inhibitor;
[GA303] H.PYLORI AGENTS;
[GA900] GASTRIC MEDICATIONS, OTHER;
=LANSOPRAZOLE;
OMEPRAZOLE 10 MG;
OMEPRAZOLE 20 MG;
OMEPRAZOLE 40 MG;
|
- 1848. 5-FU/IFN-B
- (UMLS (NCI) C0279438) =Therapeutic or Preventive Procedure
| - 1898. 5-Methoxy-N-acetyltryptamine
- [5-methoxy-N-acetyltryptamine, a pineal hormone involved in modulation of skin pigmentation, gonad development, and circadian rhythms. ( CSP )] (UMLS (NCI) C0025219) =Pharmacologic Substance; Neuroreactive Substance or Biogenic Amine; Hormone =neurohormone;
Unclassified Ingredients;
Unclassified Ingredient Preparations;
=MELATONIN CAP/TAB |
- 1849. 5-FU/IL-1B
- (UMLS (NCI) C0280480) =Therapeutic or Preventive Procedure ;
| - 1899. 5-methyltetrahydrofolate:NADP oxidoreductase
- [A flavoprotein (FAD). [EC 1.5.1.20 created 1978 as EC 1.1.1.171, transferred 1984 to EC 1.5.1.20] (from IUBMB). ( NCI )] (UMLS (NCI) C0066357) =Amino Acid, Peptide, or Protein; Enzyme ;
|
- 1850. 5-FU/IUDR
- (UMLS (NCI) C0278672) =Therapeutic or Preventive Procedure
| - 1900. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, Monosodium Salt(6R-(6alpha,7beta(Z)))-
- [The sodium salt form of cefuroxime and a semi-synthetic, broad-spectrum, beta-lactamase resistant, second-generation cephalosporin antibiotic with bactericidal activity. Cefuroxime sodium inhibits bacterial cell wall synthesis by inactivating penicillin binding proteins (PBPs) thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of the cell wall. Lack of cross-linking results in a reduction of cell wall stability and leads to cell lysis. ( NCI )] (UMLS (NCI) C0701852) =Organic Chemical; Antibiotic =CEFUROXIME;
Cefuroxime Axetil =Cefuroxime 1.5 MG/ML Injectable Solution;
CEFUROXIME SODIUM 7.5 GM/VIL;
CEFUROXIME SODIUM 30 MG/ML;
CEFUROXIME SODIUM 15 MG/ML;
CEFUROXIME SODIUM 7.5 MG/ML;
CEFUROXIME SODIUM 7.5 GM;
CEFUROXIME SODIUM 750 MG |
home
